Drugs / ICG administration
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06610071 | Oct 2024 → Dec 2028 expected | dermatofibrosarcoma protuberans, skin squamous cell carcinoma | The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICG administration | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06610071 ↗ |
| Route | Intravenous | “The ICG was injected intravenously” NCT06610071 ↗ |